Form 4: TriSalus CFO Granted Significant Performance Options

TriSalus Life Sciences' CFO, David Patience, received 248,899 performance-based stock options tied to a $75 million revenue target.

Summary

• David Patience, Chief Financial Officer of TriSalus Life Sciences, Inc. (TLSI), was granted 248,899 employee stock options.
• The options have an exercise price of $5.11 per share.
• The grant is contingent upon TriSalus achieving or exceeding $75 million in revenue over any twelve consecutive calendar months, ending on or before December 31, 2027.
• The options vest immediately upon meeting the performance requirement, provided Mr. Patience remains employed by the Issuer.
• If the $75 million revenue threshold is not met by December 31, 2027, the stock options will expire worthless.
• Following this transaction, Mr. Patience beneficially owns 538,899 derivative securities (employee stock options).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the strong alignment of executive incentives with a significant revenue growth target, indicating management's confidence and strategic focus. However, it's not overwhelmingly positive as it's a compensation event, not a direct financial performance report.

Positives

• The grant of performance-based stock options aligns the Chief Financial Officer's incentives directly with the company's revenue growth objectives.
• The $75 million revenue target by December 31, 2027, indicates a clear strategic goal for significant top-line expansion.

Negatives

• The options are entirely performance-based and will expire worthless if the $75 million revenue target is not met by December 31, 2027, introducing a risk for the reporting person.

Risks

• Failure to achieve the $75 million revenue target over any twelve consecutive calendar months by December 31, 2027, will result in the forfeiture and expiration of the granted stock options.

Future Outlook

The company has set a clear performance objective of achieving $75 million in revenue over a twelve-month period by the end of 2027, which is a key driver for executive compensation.

Management Comments

• The options vest immediately upon achieving the performance requirement, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

Industry Context

This grant reflects a common practice in the life sciences industry to incentivize executive leadership through performance-based equity awards, aligning their interests with long-term company growth and shareholder value creation. The specific revenue target suggests a focus on scaling commercial operations or achieving significant milestones in product development and market penetration.

Comparison to Industry Standards

• Performance-based stock options are a standard component of executive compensation packages across the life sciences sector, similar to those offered by companies like Moderna or BioNTech, which often tie significant equity grants to clinical trial success, regulatory approvals, or revenue milestones.
• The specific revenue target of $75 million by 2027 provides a measurable goal, comparable to growth targets seen in emerging biotech firms aiming to transition from clinical-stage to commercial-stage operations.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if the company achieves the $75 million revenue target, as this would lead to the vesting of options and likely reflect strong business performance.
• Employees: The CFO's incentive alignment could foster a performance-driven culture, potentially benefiting all employees through overall company success.

Next Steps

• The company will need to execute its business strategy to achieve the $75 million revenue target by December 31, 2027, for the options to vest.

Key Dates

Keywords

TriSalus Life Sciences, TLSI, Stock Options, Performance-Based Compensation, CFO, Insider Transaction, Revenue Target, Executive Compensation, SEC Form 4